Cite
Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
MLA
James, Stefan, et al. “Rationale and Design of the DAPA-MI Trial: Dapagliflozin in Patients without Diabetes Mellitus with Acute Myocardial Infarction.” American Heart Journal, vol. 266, Dec. 2023, pp. 188–97. EBSCOhost, https://doi.org/10.1016/j.ahj.2023.08.008.
APA
James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Björkgren, I., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Parvaresh Rizi, E., Deanfield, J., & Oldgren, J. (2023). Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. American Heart Journal, 266, 188–197. https://doi.org/10.1016/j.ahj.2023.08.008
Chicago
James, Stefan, David Erlinge, Robert F. Storey, Darren K. McGuire, Mark de Belder, Ida Björkgren, Peter A. Johansson, et al. 2023. “Rationale and Design of the DAPA-MI Trial: Dapagliflozin in Patients without Diabetes Mellitus with Acute Myocardial Infarction.” American Heart Journal 266 (December): 188–97. doi:10.1016/j.ahj.2023.08.008.